Evidence brief
Liraglutide
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Direct answer
FDA-approved products exist for specific indications.
An established prescription medicine. Its evidence applies to specific products, uses, groups of people, and current labels.
- How strong is the evidence?
- Established
An official agency review or strong, repeated studies in people support one clear use. That evidence applies only to the product, people, and use we reviewed. It does not mean the product is safe or effective for everyone. - What evidence exists?
- Approved human outcomes
Approved products have evidence from studies in people that measured health results for specific uses. This does not show that every product, person, or use has the same result. - Sports rules
- Not assessed
No current sports-rule review is available.
Reviewed July 23, 2026. Sources and update notes are below.
No sales or dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Also known as Victoza · Saxenda · GLP-1 analogue
Part of Metabolic peptide medicines
Words used here
- indication
- the approved or studied use and patient group
- outcome
- what the study measured
- analog
- a changed version made to act like another substance
- compounded
- made for one patient by a pharmacy, or in batches by a permitted outsourcing facility; a compounded drug is not FDA-approved
- comparator
- the treatment or group used for comparison
- randomized
- assigned to study groups by chance
- formulation
- the ingredients and physical form of the finished product
- receptor
- a protein in a cell that receives a body signal
More detailProduct and study details
01 · Evidence profile
Four questions about the evidence
Large randomized programs support defined glycemic, cardiovascular, and weight-management outcomes.
Approved labels characterize product-specific exposure, pharmacodynamics, and interactions.
Current labels describe contraindications, warnings, adverse reactions, and monitoring.
High for authentic approved products; evidence does not transfer automatically to unapproved versions.
02 · Identity
What it is
Liraglutide is an ingredient used in prescription medicines. GLP-1 is a body signal that helps control blood sugar and appetite. The ingredient name alone does not identify the product, use, form, or labeled group of people.
Scientific group: GLP-1 receptor agonist. This group name describes the type of molecule or body signal. It does not prove a benefit, safety, or approval.
03 · Exact product
The molecule is not the finished product.
Formulation: The finished product's ingredients and physical form. Route: How the product enters the body. Indication: The approved or studied use and group of people for a product.
Victoza
November 2024- Formulation
- Injection
- Route
- Subcutaneous
- Indication scope
- Type 2 diabetes uses and labeled populations defined in the current product prescribing information.
Saxenda
February 2026- Formulation
- Injection
- Route
- Subcutaneous
- Indication scope
- Chronic weight management in the adult and pediatric populations defined in the current label.
- Victoza
- Saxenda
- Type 2 diabetes for labeled populations
- Chronic weight management for labeled populations
04 · Research results
What the research shows
Studies and FDA-reviewed labels support specific outcomes. LEADER studied heart and blood-vessel outcomes in adults with type 2 diabetes at high cardiovascular risk. Saxenda has a separate chronic weight-management label.
These results do not show the same benefit for every person. They do not establish an anti-aging effect or show that approved products are equivalent to compounded, counterfeit, or research-labeled material.
Exact product
The ingredient name alone does not tell you which approved product the evidence covers. Liraglutide is an active ingredient. Victoza and Saxenda are distinct approved products with different labeled indications and product-specific prescribing information.
05 · Claim check
Claims I checked
3 claims checked for this brief.
“Liraglutide has established human outcome evidence.”
Yes, for defined products, populations, indications, comparators, endpoints, and durations studied in major trials and reviewed labels.
- Evidence used
- Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
- Limits of this answer
- Approved liraglutide products used in the populations and indications studied. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Every product sold as liraglutide is clinically equivalent.”
Approved-product evidence includes product quality and labeling that cannot be assumed for every compounded or unapproved item.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- Product identity, formulation, quality, and labeling all matter. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Cardiovascular trial results prove a universal longevity benefit.”
LEADER tested a defined cardiovascular composite in a high-risk type 2 diabetes population, not lifespan extension in the general population.
- Evidence used
- Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
- Limits of this answer
- Adults with type 2 diabetes and high cardiovascular risk in LEADER. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
06 · Questions
Questions people ask about Liraglutide
FDA-approved products exist for specific indications. Approved products identified: Victoza, Saxenda.
Not assessed. This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body. This status is not personal clearance to compete.
Studies and FDA-reviewed labels support specific outcomes. LEADER studied heart and blood-vessel outcomes in adults with type 2 diabetes at high cardiovascular risk. Saxenda has a separate chronic weight-management label.
These results do not show the same benefit for every person. They do not establish an anti-aging effect or show that approved products are equivalent to compounded, counterfeit, or research-labeled material.
07 · Safety
Safety limits for this record
The current label has important reasons a product may not be appropriate, plus warnings and precautions. This guide does not determine eligibility or provide dose, titration, or product-switching instructions.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
No current sports-rule review is available.
Reviewed .Check current rules for tested sport ↗08 · Sources
Read the sources
09 · Review history
Review history
Initial brief based on the current Saxenda label, LEADER, and FDA product records.
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.